The effect of CBDEX 10 in type 2 diabetes

The effect of CBDEX 10 spray on the control of biochemical parameters(HbA1c, FBS, HOMA IR) in type 2 diabetes

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121021011192N10

Enrollment

Registered

2021-02-23

Start date

2021-01-20

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabet. Type 2 diabetes mellitus without complications

Interventions

Intervention 1: Sublingual administration of 100 microgram from CBDEX 10 spray, twice daily (q12h) for 2 months along with the routine type 2 diabetes therapeutic regimen of the patient. Intervention

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: En Type 2 diabetes based on ADA (American Diabetes Association) guideline Age older than 18 years old

Exclusion criteria

Exclusion criteria: Uncontrolled seizure & untreated major depressive disorder Pregnancy & lactation eGFR less than 30 ml/min/1.73m2

Design outcomes

Primary

Measure	Time frame
Hemoglobin A1c (HbA1c) values. Timepoint: Before intervention and 60 days after initiation of daily use of spray. Method of measurement: Lab kits.	—

Secondary

Measure	Time frame
Record of Adverse drug reactions. Timepoint: During intervention. Method of measurement: Interview with patients.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShima Afshar

Shahid Beheshti University of Medical Sciences

afshar.shiima@yahoo.com+98 21 8820 9625

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026